{"nct_id":"NCT06772623","title":"Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2025-03-06","start_date_type":"ACTUAL","primary_completion_date":"2027-11","primary_completion_date_type":"ESTIMATED","completion_date":"2027-11","completion_date_type":"ESTIMATED","phases":["PHASE1","PHASE2"],"tickers":["ABBV"]}